Rodo et al’s study on six novel TB vaccine candidates MVA85A, AERAS-402, H1:IC31, H56:IC31, M72/AS01E, ID93+GLA-SE, and the licensed TB vaccine BCG showed that all vaccines preferentially induced antigen-specific CD4 T cell responses expressing Th1 cytokines; the response magnitude is the most differential characteristics among the vaccines (38). Here, CD4 is linked to tuberculosis.